½ÃÀ庸°í¼­
»óǰÄÚµå
1662634

¼¼°èÀÇ »ýüÀûÇÕ¼º 3D ÇÁ¸°ÆÃ Àç·á ½ÃÀå(-2030³â) : Çüź°, Àç·á À¯Çüº°, ±â¼úº°, ¿ëµµº°, ÃÖÁ¾ »ç¿ëÀÚº°, Áö¿ªº° ¿¹Ãø ¹× ºÐ¼®

Biocompatible 3D Printing Materials Market Forecasts to 2030 - Global Analysis By Form (Powder, Filament, Resins, Bioinks and Other Forms), Material Type, Technology, Application, End User and By Geography

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Stratistics Market Research Consulting | ÆäÀÌÁö Á¤º¸: ¿µ¹® 200+ Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Stratistics MRC¿¡ µû¸£¸é ¼¼°èÀÇ »ýüÀûÇÕ¼º 3D ÇÁ¸°ÆÃ Àç·á ½ÃÀåÀº 2024³â 12¾ï ´Þ·¯¸¦ ´Þ¼ºÇÏ¿´°í ¿¹Ãø ±â°£ µ¿¾È CAGR 21.9%·Î 2030³â 40¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.

»ýüÀûÇÕ¼º 3D ÇÁ¸°ÆÃÀº »ýü Á¶Á÷¿¡ ÀûÇÕÇÑ Àç·á¸¦ »ç¿ëÇÏ¿© 3Â÷¿ø ±¸Á¶¸¦ ¸¸µå´Â °ÍÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ¹°ÁúÀº ÀÎü¿Í Á¢ÃËÇØµµ À¯ÇØÇÑ ¹ÝÀÀÀ» ÀÏÀ¸Å°Áö ¾ÊÀ¸¹Ç·Î ÀÓÇöõÆ®, Àΰø Àåºñ, Á¶Á÷ °ñ°Ý, ¾à¹° Àü´Þ ½Ã½ºÅÛ µîÀÇ ÀÇ·á ¿ëµµ¿¡ ÀûÇÕÇÕ´Ï´Ù. ÀÌ °úÁ¤¿¡¼­´Â »ý¹°ÇÐÀû ½Ã½ºÅÛ°úÀÇ ÅëÇÕÀ» ÃËÁøÇϰí ÀÇ·á ºÐ¾ß¿¡¼­ ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±ÇÒ ¼ö ÀÖ´Â ¸ÂÃãÇü ¼Ö·ç¼ÇÀ» ¸¸µé±â À§ÇØ »ý¹°ÇÐÀûÀ¸·Î ģȭÀûÀÎ Àç·á¸¦ Á¤È®ÇÏ°Ô ÀμâÇØ¾ß ÇÕ´Ï´Ù.

¹Ì±¹ º¸°Ç»çȸ º¹ÁöºÎ¿¡ µû¸£¸é º´¿ø ³» ÀüÀÚÀǹ«±â·Ï(EHR) ½Ã½ºÅÛÀÇ »ç¿ë·üÀº 2008³â 9.4%¿¡¼­ 2021³â 96%·Î »ó½ÂÇÏ¿© µðÁöÅÐ °Ç°­ ¼Ö·ç¼Ç¿¡ Å« ¿òÁ÷ÀÓÀ» º¸¿´½À´Ï´Ù.

ÀÇ·á ¹× ÀÇ·á±â±â ¼ö¿ä Áõ°¡

ÀÇ·á ¹× ÀÇ·á±â±â ºÐ¾ßÀÇ »ýüÀûÇÕ¼º 3D ÇÁ¸°ÆÃ ¼ö¿ä Áõ°¡´Â ¸ÂÃãÇü ÀÓÇöõÆ®, º¸Ã¶¹° ¹× ¼ö¼ú ±â±¸ÀÇ Çʿ伺¿¡ ÀÇÇØ ¹ß»ýÇÕ´Ï´Ù. ÀÌ ±â¼úÀº ȯÀÚ¿¡°Ô ƯȭµÈ ¼Ö·ç¼ÇÀ» ¸¸µé ¼ö ÀÖ¾î Ä¡·á °á°ú¸¦ Çâ»ó½Ãŵ´Ï´Ù. ¶ÇÇÑ Àç»ýÀÇ·á ¹× Á¶Á÷°øÇÐÀÇ Áøº¸µµ ±â´ÉÀûÀÌ°í »ýüÀûÇÕ¼ºÀÌ ³ôÀº ±¸Á¶¸¦ ¸¸µé¾î ³»´Â »õ·Î¿î °¡´É¼ºÀ» Á¦°øÇÕ´Ï´Ù. ±× °á°ú ÀÇ·á ºÎ¹®Àº ÀÇ·á ¿ëµµ¿¡ 3D ÇÁ¸°ÆÃÀ» ºü¸£°Ô µµÀÔÇϰí ÀÖ½À´Ï´Ù.

Á¦ÇÑÀûÀÎ »ê¾÷ÀÇ Àνİú ä¿ë

»ýüÀûÇÕ¼º 3D ÇÁ¸°ÆÃ ±â¼ú¿¡ ´ëÇÑ »ê¾÷ÀÇ Àνİú ä¿ëÀÌ Á¦ÇÑÀûÀ̸ç ÀÌ´Â ÀÇ·á ºÐ¾ß¿¡¼­ 3D ÇÁ¸°ÆÃ ±â¼úÀÇ º¸±ÞÀ» ¹æÇØÇϰí ÀÖ½À´Ï´Ù. ¸¹Àº ÀÇ·á Á¦°ø¾÷üµéÀº 3D ÇÁ¸°ÆÃÀÇ °¡´É¼ºÀ» ÃæºÐÈ÷ ÀÌÇØÇÏÁö ¸øÇÏ¿© ÀÓ»ó µµÀÔÀ» ¸Á¼³À̰í ÀÖ½À´Ï´Ù. ÀÌ·Î ÀÎÇØ ¸ÂÃãÇü ÀÓÇöõÆ®, º¸Ã¶¹° ¹× Àç»ýÄ¡·áÀÇ ÇýÅÃÀÌ Áö¿¬µÉ ¼ö ÀÖ½À´Ï´Ù. °Ô´Ù°¡ ½Å±â¼ú ä¿ë¿¡ ´ëÇÑ °ÅºÎ°¨Àº ½ÃÀåÀÌ ÀáÀ缺Àå·ÂÀ» ÃæºÐÈ÷ ¹ßÈÖÇÏÁö ¸øÇÏ°Ô Çϰí Çõ½ÅÀ» Á¦ÇÑÇÏ¿© Áøº¸µÈ ÀÇ·á ¼Ö·ç¼Ç¿¡ ´ëÇÑ Á¢±ÙÀ» °¨¼Ò½Ãų ¼ö ÀÖ½À´Ï´Ù.

3D ÇÁ¸°ÆÃ Àç·áÀÇ Áøº¸

3D ÇÁ¸°ÆÃ Àç·áÀÇ ½ÅÈïÀº ½ÃÀå °³Ã´¿¡ ÇʼöÀûÀ̸ç ÀÇ·á ¿ëµµÀÇ ¾ö°ÝÇÑ ¿ä±¸»çÇ×À» ÃæÁ·ÇÏ´Â »õ·Î¿î Æú¸®¸Ó, ±Ý¼Ó ¹× ¼¼¶ó¹ÍÀÇ °³¹ßÀ» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº ÀÓÇöõÆ®, Àΰø Àåºñ, Á¶Á÷°øÇп¡ ÀûÇÕÇÑ ³»±¸¼º, À¯¿¬¼º ¹× »ýüģȭ¼ºÀÌ ³ôÀº Àç·á¸¦ °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. Àç·áÀÇ Æ¯¼ºÀÌ Çâ»óµÊ¿¡ µû¶ó ÀÇ·á¿¡¼­ 3D ÇÁ¸°ÆÃÀÇ ¹üÀ§°¡ È®´ëµÇ°í ¸ÂÃãÈ­ ´É·ÂÀÌ ³ô¾ÆÁö¸ç ȯÀÚÀÇ ¿¹Èİ¡ Çâ»óµË´Ï´Ù.

±â¼úÀû º¹À⼺

»ýüÀûÇÕ¼º 3D ÇÁ¸°ÆÃÀº ¼÷·ÃµÈ ³ëµ¿·Â, ÷´Ü Àåºñ, Àü¹® Áö½ÄÀÌ ÇÊ¿äÇϱ⠶§¹®¿¡ ±â¼úÀû º¹À⼺ÀÌ º¸±ÞÀ» ¹æÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. µû¶ó¼­ ¼Ò±Ô¸ð ÀÇ·á Á¦°ø¾÷ü¿Í Á¦Á¶¾÷ÀÚ¿¡°Ô´Â ´ë·®ÀÇ ÅõÀÚ¸¦ ÇÏÁö ¾ÊÀ¸¸é µµÀÔÀÌ ¾î·Á¿î ±â¼úÀÔ´Ï´Ù. ¶ÇÇÑ º¹ÀâÇÑ ¼³°è, ÀÎ¼â ¹× ÈÄó¸® ÇÁ·Î¼¼½º´Â »ý»ê ±â°£À» Àå±âÈ­ÇÏ°í ºñ¿ëÀ» Áõ°¡½ÃÄÑ ÀÇ·á ºÎ¹®¿¡¼­ È¿À²¼º°ú È®À强À» Á¦ÇÑÇÏ°í ½ÃÀå ¼ºÀåÀ» µÐÈ­½Ãų ¼ö ÀÖ½À´Ï´Ù.

COVID-19ÀÇ ¿µÇâ

ÀÌ ½ÃÀåÀº ¸ÂÃãÇü ÀÇ·á Àåºñ, ÀÓÇöõÆ® ¹× º¸Ã¶¹°À» °¡´ÉÇÏ°Ô ÇÔÀ¸·Î½á ÀÇ·á¿¡ Çõ¸íÀ» ÀÏÀ¸Å°°í ÀÖ½À´Ï´Ù. ¸ÂÃãÇü ¼Ö·ç¼ÇÀ» ÅëÇØ ȯÀÚ ¿¹Èĸ¦ °³¼±Çϰí Àç»ýÀÇ·á ¹× Á¶Á÷°øÇÐÀÇ Áøº¸¸¦ ÃËÁøÇÕ´Ï´Ù. ¶ÇÇÑ ÀÌ ±â¼úÀº »ý»ê È¿À²¼ºÀ» ³ôÀÌ°í ºñ¿ëÀ» Àý°¨Çϸç Ä¡·á Çõ½ÅÀ» °¡¼ÓÈ­ÇÕ´Ï´Ù. ±×·¯³ª °íºñ¿ë, ±â¼ú º¹À⼺, ±ÔÁ¦ Àå¾Ö¹°°ú °°Àº ¹®Á¦´Â ½ÃÀå ÀáÀç·Â¿¡ ¿µÇâÀ» ÁÙ ¼ö ÀÖ½À´Ï´Ù.

¿¹Ãø ±â°£ µ¿¾È Çʶó¸àÆ® ºÎ¹®ÀÌ ÃÖ´ë·Î ¼ºÀåÇÒ Àü¸Á

¿¹Ãø ±â°£ µ¿¾È Çʶó¸àÆ® ºÎ¹®ÀÌ ÃÖ´ë ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ Çʶó¸àÆ®´Â »ýüÀûÇÕ¼º °íºÐÀÚ, ±Ý¼Ó ¶Ç´Â ¼¼¶ó¹ÍÀ¸·Î ¸¸µé¾îÁ³À¸¸ç Àΰ£ÀÌ »ç¿ëÇÏ´õ¶óµµ ¾ÈÀüÇϰí Á¶Á÷ ÅëÇÕÀ» ÃËÁøÇϵµ·Ï ¼³°èµÇ¾ú½À´Ï´Ù. Çʶó¸àÆ® ±â¼úÀÇ Çõ½ÅÀº °­µµ, À¯¿¬¼º ¹× »ý¹°ÇÐÀû Ȱµ¿À» Çâ»ó½ÃŰ°í ¸ÂÃãÇü ÀÇ·á ¼Ö·ç¼ÇÀÇ ÀáÀç·ÂÀ» ³ÐÇôÁÝ´Ï´Ù. ±×·¯³ª Àç·áÀÇ ÇѰè¿Í Á¦Á¶ ºñ¿ëÀº º¸±ÞÀ» À§ÇÑ °úÁ¦°¡ µÇ°í ÀÖ½À´Ï´Ù.

¿¹Ãø ±â°£ µ¿¾È Á¶Á÷°øÇÐ ºÎ¹®ÀÇ CAGRÀÌ °¡Àå ³ôÀ» °ÍÀ¸·Î ¿¹»ó

¿¹Ãø ±â°£ µ¿¾È Á¶Á÷°øÇÐ ºÎ¹®ÀÌ °¡Àå ³ôÀº ¼ºÀå·üÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. 3D ÇÁ¸°ÆÃÀº õ¿¬ Á¶Á÷À» ¸ð¹æÇÑ ±¸Á¶ÀÇ Á¤¹ÐÇÑ ¼³°è¸¦ °¡´ÉÇÏ°Ô ÇÏ¿© Àç»ýÀÇ·áÀÇ Áøº¸¸¦ °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. »ýüÀûÇÕ¼º Àç·á¸¦ »ç¿ëÇÑ °ñ°ÝÀº Ä¡À¯¸¦ ÃËÁøÇÏ°í ±Ã±ØÀûÀ¸·Î Àå±â À̽Ŀ¡ µµ¿òÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ±â¼úÀº ºÎ»ó°ú Áúº´ÀÇ Ä¡·á¿¡ Å« ÀáÀç·ÂÀ» °¡Áö°í ÀÖÁö¸¸ Àç·á °³¹ß ¹× ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎÀ̶ó´Â °úÁ¦¿¡ Á÷¸éÇϰí ÀÖ½À´Ï´Ù.

ÃÖ´ë Á¡À¯À² Áö¿ª

¿¹Ãø ±â°£ µ¿¾È ºÏ¹Ì´Â ÷´Ü ÀÇ·á ÀÎÇÁ¶ó¿Í ¸ÂÃãÇü ÀÇ·á±â±â¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î ÀÎÇØ ÃÖ´ë ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¹Ì±¹°ú ij³ª´Ù´Â ÀÓÇöõÆ®, º¸Ã¶ ¹× Á¶Á÷°øÇÐ ºÐ¾ßÀÇ 3D ÇÁ¸°ÆÃ µµÀÔÀ¸·Î ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. »ýüÀûÇÕ¼º Àç·áÀÇ ±â¼úÀû Áøº¸¿Í ÇÔ²² ±ÔÁ¦ Áö¿øÀº ½ÃÀå ¼ºÀåÀ» ´õ¿í °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù. ±×·¯³ª ³ôÀº ºñ¿ë°ú ±â¼úÀû º¹À⼺ÀÌ Áö¿ª ³» º¸±Þ¿¡ °úÁ¦°¡ µÇ°í ÀÖ½À´Ï´Ù.

CAGRÀÌ °¡Àå ³ôÀº Áö¿ª

¿¹Ãø ±â°£ µ¿¾È ¾Æ½Ã¾ÆÅÂÆò¾çÀÌ °¡Àå ³ôÀº CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Àεµ ¹× µ¿³²¾Æ½Ã¾Æ¿Í °°Àº ½ÅÈï ±¹°¡ ³» ÀÇ·á ºÎ¹®ÀÇ È®´ë´Â ¼ö¼ú °èȹ ¸ðµ¨, ÀÓÇöõÆ®, Àåºñ µî ÀÇ·á ¿ëµµ¿¡¼­ 3D ÇÁ¸°ÆÃ ¼ö¿ä¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÌ Áö¿ª¿¡¼­´Â Ä¡°ú¿ë ÀÓÇöõÆ®, º¸Ã»±â, Àΰø°üÀý Á¦Á¶¿¡ Á¡Â÷ 3D ÇÁ¸°Å͸¦ »ç¿ëÇϰí ÀÖ½À´Ï´Ù.

»ç¿ëÀÚ Á¤ÀÇ ¹«·á Á¦°ø

ÀÌ º¸°í¼­¸¦ ±¸µ¶ÇÏ´Â °í°´¿¡°Ô´Â ´ÙÀ½ ¹«·á ¸ÂÃãÇü ¿É¼Ç Áß Çϳª°¡ Á¦°øµË´Ï´Ù.

  • ±â¾÷ ÇÁ·ÎÆÄÀÏ
    • Ãß°¡ ½ÃÀå ÁøÃâ±â¾÷ÀÇ Á¾ÇÕÀû ÇÁ·ÎÆÄÀϸµ(ÃÖ´ë 3°³»ç)
    • ÁÖ¿ä ±â¾÷ÀÇ SWOT ºÐ¼®(ÃÖ´ë 3°³»ç)
  • Áö¿ª ¼¼ºÐÈ­
    • °í°´ÀÇ °ü½É¿¡ ¸ÂÃá ÁÖ¿ä±¹ ½ÃÀå ÃßÁ¤, ¿¹Ãø ¹× CAGR(ÁÖ : Ÿ´ç¼º ºÐ¼®¿¡ µû¸§)
  • °æÀï º¥Ä¡¸¶Å·
    • Á¦Ç° Æ÷Æ®Æú¸®¿À, Áö¸®Àû Á¸Àç, Àü·«Àû Á¦ÈÞ¸¦ ÅëÇÑ ÁÖ¿ä ±â¾÷ º¥Ä¡¸¶Å·

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ¼­¹®

  • °³¿ä
  • ÀÌÇØ°ü°èÀÚ
  • Á¶»ç ¹üÀ§
  • Á¶»ç ¹æ¹ý
    • µ¥ÀÌÅÍ ¸¶ÀÌ´×
    • µ¥ÀÌÅÍ ºÐ¼®
    • µ¥ÀÌÅÍ °ËÁõ
    • Á¶»ç Á¢±Ù
  • Á¶»ç Á¤º¸¿ø
    • 1Â÷ Á¶»ç Á¤º¸¿ø
    • 2Â÷ Á¶»ç Á¤º¸¿ø
    • ÀüÁ¦Á¶°Ç

Á¦3Àå ½ÃÀå µ¿Ç⠺м®

  • ¼Ò°³
  • ¼ºÀå ÃËÁø¿äÀÎ
  • ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ±âȸ
  • À§Çù
  • ±â¼ú ºÐ¼®
  • ¿ëµµ ºÐ¼®
  • ÃÖÁ¾ »ç¿ëÀÚ ºÐ¼®
  • ½ÅÈï ½ÃÀå
  • COVID-19ÀÇ ¿µÇâ

Á¦4Àå Porter's Five Forces ºÐ¼®

  • °ø±Þ±â¾÷ÀÇ Çù»ó·Â
  • ±¸¸ÅÀÚÀÇ Çù»ó·Â
  • ´ëüǰÀÇ À§Çù
  • ½Å±Ô Âü°¡¾÷üÀÇ À§Çù
  • °æÀï ±â¾÷°£ °æÀï °ü°è

Á¦5Àå ¼¼°èÀÇ »ýüÀûÇÕ¼º 3D ÇÁ¸°ÆÃ Àç·á ½ÃÀå : Çüź°

  • ¼Ò°³
  • ºÐ¸»
  • Çʶó¸àÆ®
  • ¼öÁö
  • ¹ÙÀÌ¿ÀÀ×Å©
  • ±âŸ

Á¦5Àå ¼¼°èÀÇ »ýüÀûÇÕ¼º 3D ÇÁ¸°ÆÃ Àç·á ½ÃÀå : Àç·á À¯Çüº°

  • ¼Ò°³
  • Æú¸®¸Ó
  • ±Ý¼Ó
  • ¼¼¶ó¹Í
  • º¹ÇÕÀç·á
  • ±âŸ

Á¦7Àå ¼¼°èÀÇ »ýüÀûÇÕ¼º 3D ÇÁ¸°ÆÃ Àç·á ½ÃÀå : ±â¼úº°

  • ¼Ò°³
  • ¿­ ¿ëÇØ ÀûÃþ¹ý(FDM)
  • ½ºÅ×·¹¿À¸®¼Ò±×·¡ÇÇ(SLA)
  • ¼±ÅÃÀû ·¹ÀÌÀú ¼Ò°á(SLS)
  • ¹ÙÀÌ¿ÀÇÁ¸°ÆÃ

Á¦8Àå ¼¼°èÀÇ »ýüÀûÇÕ¼º 3D ÇÁ¸°ÆÃ Àç·á ½ÃÀå : ¿ëµµº°

  • ¼Ò°³
  • ÀÇ·á ÀÓÇöõÆ®
  • Á¶Á÷°øÇÐ
  • º¸Ã¶
  • ¾à¹° Àü´Þ ½Ã½ºÅÛ
  • ¼ö¼ú±â±¸
  • ±âŸ

Á¦9Àå ¼¼°èÀÇ »ýüÀûÇÕ¼º 3D ÇÁ¸°ÆÃ Àç·á ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°

  • ¼Ò°³
  • º´¿ø ¹× Ŭ¸®´Ð
  • ¿¬±¸±â°ü
  • ÀÇ·á±â±â Á¦Á¶¾÷ü
  • Çмú±â°ü
  • ±âŸ

Á¦10Àå ¼¼°èÀÇ »ýüÀûÇÕ¼º 3D ÇÁ¸°ÆÃ Àç·á ½ÃÀå : Áö¿ªº°

  • ¼Ò°³
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • È£ÁÖ
    • ´ºÁú·£µå
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ³²¹Ì
    • ¾Æ¸£ÇîÆ¼³ª
    • ºê¶óÁú
    • Ä¥·¹
    • ±âŸ ³²¹Ì
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • īŸ¸£
    • ³²¾ÆÇÁ¸®Ä«
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦11Àå ÁÖ¿ä °³¹ß

  • °è¾à/ÆÄÆ®³Ê½Ê/Çù¾÷/ÇÕÀÛÅõÀÚ(JV)
  • Àμö ¹× ÇÕº´
  • ½ÅÁ¦Ç° ¹ß¸Å
  • »ç¾÷ È®´ë
  • ±âŸ ÁÖ¿ä Àü·«

Á¦12Àå ±â¾÷ ÇÁ·ÎÆÄÀϸµ

  • Stratasys Ltd.
  • 3D Systems
  • Materialise NV
  • Formlabs
  • Sculpteo
  • Carbon, Inc.
  • EnvisionTEC
  • EOS GmbH
  • BASF 3D Printing Solutions
  • HP Inc.
  • Tethon 3D
  • Protolabs
  • Optomec
  • Regemat 3D
  • Fiocruz
CSM 25.03.18

According to Stratistics MRC, the Global Biocompatible 3D Printing Materials Market is accounted for $1.2 billion in 2024 and is expected to reach $4.0 billion by 2030 growing at a CAGR of 21.9% during the forecast period. Biocompatible 3D printing is the use of materials that are compatible with living tissue to create three-dimensional structures. These materials do not cause harmful reactions when in contact with the human body, making them suitable for medical applications such as implants, prosthetics, tissue scaffolds, and drug delivery systems. The process involves precise printing of bio-friendly materials to create custom-made solutions that can promote healing, integration with biological systems, and improve patient outcomes in healthcare.

According to the United States Department of Health and Human Services, the use of basic Electronic Health Record (EHR) systems in hospitals went from 9.4% in 2008 to 96% in 2021 demonstrating a significant move toward digital health solutions.

Market Dynamics:

Driver:

Increasing demand in healthcare and medical devices

The increasing demand for biocompatible 3D printing in healthcare and medical devices is driven by the need for personalized, custom-fit implants, prosthetics, and surgical tools. This technology enables the creation of patient-specific solutions, improving treatment outcomes. Additionally, it supports advancements in regenerative medicine and tissue engineering, offering new possibilities for creating functional, biocompatible structures. As a result, the healthcare sector is rapidly adopting 3D printing for medical applications.

Restraint:

Limited industry awareness and adoption

Limited industry awareness and adoption of biocompatible 3D printing technology hinders its widespread use in healthcare. Many healthcare providers may not fully understand its potential, leading to slow integration into clinical practice. This can delay the benefits of customized implants, prosthetics, and regenerative treatments. Additionally, resistance to adopting new technologies can prevent the market from realizing its full growth potential, limiting innovation and reducing access to advanced medical solutions.

Opportunity:

Advances in 3D printing materials

Advances in 3D printing materials are crucial for the market, enabling the development of new polymers, metals, and ceramics that meet the stringent requirements of medical applications. These innovations allow for more durable, flexible, and bio-friendly materials suitable for implants, prosthetics, and tissue engineering. As material properties improve, the scope of 3D printing in healthcare expands, fostering greater customization and enhancing patient outcomes in medical treatments.

Threat:

Technical complexity

The technical complexity of biocompatible 3D printing can hinder its widespread adoption, as it requires skilled labor, advanced equipment, and specialized knowledge. This makes the technology difficult to implement for smaller healthcare providers or manufacturers without significant investment. Additionally, the intricate design, printing, and post-processing steps can lead to longer production times and increased costs, limiting efficiency and scalability in the healthcare sector, and slowing market growth.

Covid-19 Impact:

The market is revolutionizing healthcare by enabling the creation of personalized medical devices, implants, and prosthetics. It enhances patient outcomes through customized solutions, while fostering advancements in regenerative medicine and tissue engineering. Additionally, the technology improves production efficiency, reduces costs, and accelerates innovation in medical treatments. However, challenges such as high costs, technical complexity, and regulatory hurdles can impact its full market potential.

The filament segment is expected to be the largest during the forecast period

The filament segment is expected to account for the largest market share during the forecast period. These filaments, made from biocompatible polymers, metals, or ceramics, are designed to be safe for human use and promote tissue integration. Innovations in filament technology improve strength, flexibility, and bioactivity, expanding the possibilities for customized medical solutions. However, material limitations and production costs still present challenges for widespread adoption.

The tissue engineering segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the tissue engineering segment is predicted to witness the highest growth rate. 3D printing allows for the precise design of structures mimicking natural tissues, enabling advancements in regenerative medicine. By using biocompatible materials, these printed scaffolds promote healing and may eventually aid in organ replacement. This technology holds great promise for treating injuries and diseases but faces challenges in material development and regulatory approval.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share driven by advanced healthcare infrastructure and increasing demand for personalized medical devices. The U.S. and Canada lead in adopting 3D printing for implants, prosthetics, and tissue engineering. Regulatory support, alongside technological advancements in biocompatible materials, is further accelerating market growth. However, high costs and technical complexities remain challenges for widespread adoption in the region.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR. The expansion of the healthcare sector in emerging economies such as India and Southeast Asia is contributing to the demand for 3D printing in medical applications, including surgical planning models, implants, and orthotic devices. Additionally, the use of 3D printers in the production of dental implants, hearing aids, and joint replacements is becoming more widespread in the region.

Key players in the market

Some of the key players in Biocompatible 3D Printing Materials market include Stratasys Ltd., 3D Systems, Materialise NV, Formlabs, Sculpteo, Carbon, Inc., EnvisionTEC, EOS GmbH, BASF 3D Printing Solutions, HP Inc., Tethon 3D, Protolabs, Optomec, Regemat 3D and Fiocruz.

Key Developments:

In September 2024, Fiocruz made an investment in affordable, open-source 3D bioprinters developed in partnership with the Oswaldo Cruz Institute and Veiga de Almeida University. This technology was intended to produce artificial biological tissues for various applications, including biomedical research, healthcare, and the food industry, utilizing bioink rather than conventional printing materials.

In April 2024, Materialise and Renishaw announced a partnership to enhance efficiency and productivity for manufacturers using Renishaw's RenAM 500 series of additive manufacturing systems. This collaboration provides Renishaw users access to Materialise's advanced build processor software and Magics for data preparation, enabling a streamlined workflow from design to finished part, while optimizing production time and operations.

Forms Covered:

  • Powder
  • Filament
  • Resins
  • Bioinks
  • Other Forms

Material Types Covered:

  • Polymers
  • Metals
  • Ceramics
  • Composites
  • Other Material Types

Technologies Covered:

  • Fused Deposition Modeling (FDM)
  • Stereolithography (SLA)
  • Selective Laser Sintering (SLS)
  • Bioprinting

Applications Covered:

  • Medical Implants
  • Tissue Engineering
  • Prosthetics
  • Drug Delivery Systems
  • Surgical Instruments
  • Other Applications

End Users Covered:

  • Hospitals and Clinics
  • Research Institutes
  • Medical Device Manufacturers
  • Academic Institutions
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Biocompatible 3D Printing Materials Market, By Form

  • 5.1 Introduction
  • 5.2 Powder
  • 5.3 Filament
  • 5.4 Resins
  • 5.5 Bioinks
  • 5.6 Other Forms

5 Global Biocompatible 3D Printing Materials Market, By Material Type

  • 6.1 Introduction
  • 6.2 Polymers
  • 6.3 Metals
  • 6.4 Ceramics
  • 6.5 Composites
  • 6.6 Other Material Types

7 Global Biocompatible 3D Printing Materials Market, By Technology

  • 7.1 Introduction
  • 7.2 Fused Deposition Modeling (FDM)
  • 7.3 Stereolithography (SLA)
  • 7.4 Selective Laser Sintering (SLS)
  • 7.5 Bioprinting

8 Global Biocompatible 3D Printing Materials Market, By Application

  • 8.1 Introduction
  • 8.2 Medical Implants
  • 8.3 Tissue Engineering
  • 8.4 Prosthetics
  • 8.5 Drug Delivery Systems
  • 8.6 Surgical Instruments
  • 8.7 Other Applications

9 Global Biocompatible 3D Printing Materials Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals and Clinics
  • 9.3 Research Institutes
  • 9.4 Medical Device Manufacturers
  • 9.5 Academic Institutions
  • 9.6 Other End Users

10 Global Biocompatible 3D Printing Materials Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Stratasys Ltd.
  • 12.2 3D Systems
  • 12.3 Materialise NV
  • 12.4 Formlabs
  • 12.5 Sculpteo
  • 12.6 Carbon, Inc.
  • 12.7 EnvisionTEC
  • 12.8 EOS GmbH
  • 12.9 BASF 3D Printing Solutions
  • 12.10 HP Inc.
  • 12.12 Tethon 3D
  • 12.12 Protolabs
  • 12.13 Optomec
  • 12.14 Regemat 3D
  • 12.15 Fiocruz
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦